New hope for hepatitis b: experimental combo aims to clear the virus
NCT ID NCT04856085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on antiviral therapy took part. The goal was to see if these combinations could achieve undetectable virus levels and possibly allow patients to stop lifelong medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
San Francisco, California, 94143, United States
-
Investigative Site
Miami, Florida, 33136, United States
-
Investigative Site
Orlando, Florida, 32803, United States
-
Investigative Site
Baltimore, Maryland, 21218, United States
-
Investigative Site
Hillsborough, New Jersey, 08844, United States
-
Investigative Site
Toronto, 2C4, Canada
-
Investigative Site
Toronto, 3M1, Canada
-
Investigative Site
Vancouver, 2C7, Canada
-
Investigative Site
Frankfurt, 60590, Germany
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Mannheim, 68167, Germany
-
Investigative Site
Hong Kong, Shatin, Hong Kong
-
Investigative Site
Hong Kong, Tai Po District, Hong Kong
-
Investigative Site
Hong Kong, Hong Kong
-
Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Investigative Site
Chisinau, MD 2025, Moldova
-
Investigative Site
Auckland, 1010, New Zealand
-
Investigative Site
Auckland, 2025, New Zealand
-
Investigative Site
Hamilton, 3204, New Zealand
-
Investigative Site
Tauranga, 3110, New Zealand
-
Investigative Site
Wellington, 6021, New Zealand
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Busan, 49421, South Korea
-
Investigative Site
Seoul, 03080, South Korea
-
Investigative Site
Seoul, 05505, South Korea
-
Investigative Site
Yangsan, 50612, South Korea
-
Investigative Site
Chiayi City, 60041, Taiwan
-
Investigative Site
Kaohsiung City, 80756, Taiwan
-
Investigative Site
Kaohsiung City, 83301, Taiwan
-
Investigative Site
Taichung, 40705, Taiwan
-
Investigative Site
Taipei, 100, Taiwan
-
Investigative Site
Taoyuan City, 33305, Taiwan
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
Birmingham, B15 2TH, United Kingdom
-
Investigative Site
London, E11FR, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo finally beat chronic hepatitis b?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Experimental drug aims for functional cure in hepatitis b
- 10-Year hepatitis study aims to unlock secrets of liver disease
- New shot aims to tame hepatitis b without daily pills
- New injection aims to tame chronic hepatitis b